MedTrace Logo

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

NCT05156268 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-04-27

No results posted yet for this study

Summary

The purpose of this study is to find out whether the combination of pembrolizumab and olaparib is an effective treatment for people with persistent or recurrent endometrial cancer or endometrial carcinosarcoma. The researchers will also look at the safety of the drug combination and whether it causes few or mild side effects in participants.

Conditions

  • Endometrial Carcinosarcoma

Interventions

DRUG

Pembrolizumab

Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.

DRUG

Olaparib

Olaparib will be administered orally at 300 mg every 12 hours.

Sponsors & Collaborators

Principal Investigators

  • Maria Rubinstein, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-27
Primary Completion
2026-04-24
Completion
2026-04-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05156268 on ClinicalTrials.gov